Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and lowers the price target from $196 to $182.
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and lowers the price target from $196 to $182.